Clinical Observation of Modified Zhigancao Tang in Treating Patients with Liver and Kidney Deficiency of Parkinson's Disease and Its Effect on Neuronal Signal-related Proteins
10.13422/j.cnki.syfjx.20241525
- VernacularTitle:变通炙甘草汤治疗肝肾不足型帕金森病患者的临床观察及对神经元信号相关蛋白的影响
- Author:
Yifo WEI
1
;
Furong LYU
1
;
Jia YAO
1
;
Guonian LI
2
;
Xianyi LUO
3
;
Meng LUO
1
;
Zhengzheng WEN
1
;
Qiuqi LI
1
;
Yihan LIU
1
;
Linlin YANG
1
;
Rui ZUO
1
;
Wenxin DANG
1
;
Fang MI
1
;
Xiaoyan WANG
1
;
Zhigang CHEN
4
;
Fan LIU
1
Author Information
1. Xi'an Hospital of Traditional Chinese Medicine（TCM）， Xi'an 710016， China
2. Gem Flower Xi'an Changqing Staff Hospital， Xi'an 710201， China
3. Xi'an Yanliang District Hospital of TCM， Xi'an 710089， China
4. Dongfang Hospital， Beijing University of Chinese Medicine， Beijing 100078， China
- Publication Type:Journal Article
- Keywords:
Parkinson's disease;
α-Synuclein;
neuronal signal communication;
microtubule transport;
modified Zhigancao Tang
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2025;31(4):166-173
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveMicrotube associated protein-2 （MAP-2）， alpha-tubulin （α-tubulin）， and synaptophysin （SYP） are important proteins in neuronal signal communication. This paper observed the effects of modified Zhigancao Tang on the expression of serum α-Synuclein （α-Syn） and its oligomers， MAP-2， α-tubulin， and SYP of patients with liver and kidney deficiency of Parkinson's disease （PD）， analyzed their correlation， and evaluated the therapeutic effect of modified Zhigancao Tang in patients with liver and kidney deficiency of PD based on α-Syn transmission pathway mediated by neuronal communication in vivo. MethodsA total of 60 patients with PD who met the inclusion criteria were randomly divided into a treatment group （30 cases） and a control group （30 cases）. Both groups were treated on the basis of PD medicine， and the treatment group was treated with modified Zhigancao Tang. Both groups were treated for 12 weeks. The changes in UPDRS score， TCM syndrome score， and expression of serum α-Syn and its oligomers， MAP-2， α-tubulin， and SYP were observed before and after 12 weeks of treatment in each group. The correlation between the above-mentioned serum biological indexes and the levels of serum α-Syn and its oligomers was analyzed. ResultsAfter treatment， the TCM syndrome score， UPDRS score， UPDRS-Ⅱ score， and UPDRS-Ⅲ score of the treatment group were significantly decreased （P<0.05， P<0.01）. The UPDRS score， UPDRS-Ⅱ score， and UPDRS-Ⅲ scores in the treatment group were significantly decreased compared with those in the control group after treatment （P<0.05）. After treatment， the total effective rate of the control group was 63.3% （19/30）， and that of the treatment group was 86.7% （26/30）. The clinical effect of the observation group was better than the control group （Z=-2.03， P<0.05）. The total effective rate of the observation group was better than that of the control group， and the difference was statistically significant （χ2=5.136， P<0.05）. After treatment， the oligomer level of serum α-Syn and MAP-2 level in the treatment group were significantly decreased （P<0.05， P<0.01）. The levels of serum α-Syn and its oligomers， as well as α-tubulin in the treatment group， were significantly decreased compared with those in the control group after treatment （P<0.05， P<0.01）. Serum α-Syn was correlated with serum MAP-2 and α-Syn oligomer in patients with PD （P<0.05， P<0.01） but not correlated with serum SYP . Serum α-Syn oligomers of patients with PD were correlated with serum MAP-2 and α-tubulin （P<0.05， P<0.01） but not correlated with serum SYP level. Serum SYP of patients with PD was correlated with serum MAP-2 （P<0.05）. ConclusionModified Zhigancao Tang has a therapeutic effect on patients with liver and kidney deficiency of PD by inhibiting the production of α-Syn oligomers and intervening α-Syn microtubule transport pathway in vivo.
